Skip Content

UK wide immunotherapy trial for pancreatic cancer launched

14 April 2011

More than 1,000 people around the UK with advanced pancreatic cancer are taking part in a UK clinical trial to test the effectiveness of a new vaccine.

More than 1,000 people around the UK with advanced pancreatic cancer are taking part in a UK clinical trial to test the effectiveness of a new vaccine.

The Telovac trial, which is being carried out across 53 UK hospitals, involves patients being given regular doses of a new vaccine together with chemotherapy.

Doctors usually treat advanced pancreatic cancer with gemcitabine and capecitabine chemotherapy. But there is evidence suggesting that using immunotherapy (which uses biological substances or drugs made from these substances to stimulate the body’s immune system) together with chemotherapy, may give better results.

Results are expected to be published in just over a year’s time, and will compare the effectiveness of this combined approach with chemotherapy alone.

The trial is being funded by Cancer Research UK. The charity is keen to stress that the vaccine is not a cure, but if it works, may prolong life.

Read the full BBC News article here.

< Back